From the astonishing statistic that one in every twenty Americans is a cancer survivor to the projected surge of millions more by 2040, the story of survivorship is one of remarkable medical progress intertwined with profound, lifelong challenges that shape a community now numbering in the tens of millions worldwide.
Key Takeaways
- As of January 2022, there were an estimated 18.1 million people with a history of cancer in the United States, representing about 5.4% of the population.
- By 2040, the population of cancer survivors in the US is projected to grow to more than 26 million, a 34% increase from 2022.
- Breast cancer survivors make up the largest group at 4.1 million (22.7%) of all US cancer survivors as of 2022.
- The 5-year relative survival rate for all cancers combined (2017-2021) is 68.6% in the US.
- Breast cancer 5-year relative survival rate is 91.1% (2017-2021 SEER data).
- Prostate cancer 5-year survival rate reaches 97.1% for localized disease (2017-2021).
- Among US cancer survivors, 35% report poor health-related quality of life (HRQoL).
- 25% of cancer survivors experience serious psychological distress compared to 7% general population.
- Cancer survivors are 1.6 times more likely to report disability than non-cancer adults.
- Cancer survivors face a 70% higher risk of cardiovascular disease.
- Second primary cancers occur in 10-15% of long-term survivors.
- 30-year cumulative risk of second malignancy is 18% for Hodgkin survivors.
- 18% of survivors unemployed 1-5 years post-diagnosis vs. 10% controls.
- Annual medical costs for survivors average $11,000 higher than non-cancer.
- 42% of survivors report financial hardship due to cancer costs.
Millions are thriving as cancer survivors, with their growing numbers shaping healthcare needs.
Late Effects
- Cancer survivors face a 70% higher risk of cardiovascular disease.
- Second primary cancers occur in 10-15% of long-term survivors.
- 30-year cumulative risk of second malignancy is 18% for Hodgkin survivors.
- Osteoporosis risk is doubled in survivors treated with aromatase inhibitors.
- Childhood cancer survivors have 9-fold increased risk of subsequent malignancy.
- Cardiotoxicity from anthracyclines affects 10% of pediatric survivors long-term.
- Pulmonary toxicity persists in 25% of survivors post-chemotherapy.
- Hypothyroidism develops in 20-30% of Hodgkin lymphoma survivors.
- 15% of breast cancer survivors develop congestive heart failure post-treatment.
- Chronic kidney disease risk is 4-6 times higher in survivors.
- 25% of testicular cancer survivors have metabolic syndrome 10 years post-treatment.
- Radiation-induced secondary sarcomas risk is 1-2% at 10 years for breast survivors.
- 40% of survivors experience treatment-induced infertility.
- Osteopenia/osteoporosis in 50% of long-term childhood survivors.
- 20% of colorectal survivors develop bowel dysfunction chronically.
- Increased diabetes risk by 20% among cancer survivors.
- Hearing loss in 20% of cisplatin-treated survivors.
- 10-15% risk of endometrial cancer in tamoxifen users post-breast ca.
- Chronic graft-vs-host disease in 50% of allogeneic transplant survivors.
- 30% of survivors have subclinical hypothyroidism.
- Breast cancer survivors have 2.4-fold increased risk of atrial fibrillation.
- 5-10% of survivors develop myelodysplastic syndrome post-chemo.
- Vision impairment in 15% of pediatric brain tumor survivors.
- 25% higher fracture risk in hormone-treated prostate survivors.
- Chronic fatigue syndrome-like symptoms in 28% of survivors.
Late Effects Interpretation
Surviving cancer is a monumental victory, yet these statistics show the battle's shadow is a long and treacherous corridor filled with new, unwelcome health challenges knocking at the door.
Prevalence
- As of January 2022, there were an estimated 18.1 million people with a history of cancer in the United States, representing about 5.4% of the population.
- By 2040, the population of cancer survivors in the US is projected to grow to more than 26 million, a 34% increase from 2022.
- Breast cancer survivors make up the largest group at 4.1 million (22.7%) of all US cancer survivors as of 2022.
- Prostate cancer survivors number approximately 3.3 million (18.4%) of total US cancer survivors in 2022.
- Colorectal cancer survivors total 1.6 million (8.8%) in the US as of 2022.
- Melanoma survivors stand at 1.0 million (5.7%) of US cancer survivors in 2022.
- Female survivors represent 53.9% of all US cancer survivors, while males are 46.1% as of 2022.
- About 72.6% of US cancer survivors are aged 65 or older in 2022.
- Roughly 22.3% of cancer survivors were diagnosed under age 65 in the US in 2022.
- Cancer survivors aged 70-79 comprise the largest age group at 24.5% of total survivors in 2022.
- Non-Hispanic white individuals account for 76.8% of US cancer survivors in 2022.
- Hispanic cancer survivors make up 5.2% of the total US survivor population in 2022.
- In Europe, there were an estimated 42 million cancer survivors (both prevalent and cured) in 2020.
- Childhood cancer survivors (diagnosed before age 20) number over 500,000 in the US as of 2020.
- 5-year cancer prevalence in the US is approximately 6.2 million people alive 5 years post-diagnosis.
- 10-year cancer prevalence reaches about 5.8 million in the US.
- Globally, there are over 50 million people living within 5 years of a cancer diagnosis as of recent estimates.
- In Canada, cancer survivors total 675,000 (1 in 44 Canadians) living with or beyond cancer in 2022.
- Australian cancer survivors number 1.1 million as of 2023, expected to reach 1.6 million by 2040.
- In the UK, over 3 million people are living with cancer as of 2023.
- US cancer survivors diagnosed 20+ years ago number 5.5 million in 2022.
- Survivors of multiple primary cancers total 1.0 million (5.5%) in the US in 2022.
- Lung cancer survivors comprise 608,000 (3.4%) of US total in 2022.
- Bladder cancer survivors number 859,000 (4.8%) in the US as of 2022.
- Kidney cancer survivors total 962,000 (5.3%) of US survivors in 2022.
- Uterine corpus cancer survivors are 907,000 (5.0%) in the US in 2022.
- Thyroid cancer survivors number 936,000 (5.2%) as of 2022 in the US.
- Non-Hodgkin lymphoma survivors total 884,000 (4.9%) in 2022 US data.
- Leukemia survivors are 576,000 (3.2%) of total US cancer survivors in 2022.
- In 2022, 67.1% of US female cancer survivors had breast or gynecologic cancers.
Prevalence Interpretation
The sheer size and projected growth of the cancer survivor community—over 18 million strong in the US alone, marching toward 26 million—proves that while cancer is a formidable foe, humanity's resilience is an even greater force, one survivor at a time.
Quality of Life
- Among US cancer survivors, 35% report poor health-related quality of life (HRQoL).
- 25% of cancer survivors experience serious psychological distress compared to 7% general population.
- Cancer survivors are 1.6 times more likely to report disability than non-cancer adults.
- 17% of survivors aged 18-64 are unable to work due to health issues.
- Fatigue affects 75-90% of cancer survivors during treatment and persists in 30% long-term.
- 30-40% of breast cancer survivors report persistent cognitive impairment ("chemo brain").
- Sexual dysfunction impacts 40-100% of cancer survivors depending on site treated.
- 20-30% of survivors experience chronic pain post-treatment.
- Depression rates are 22% among cancer survivors vs. 13% in general population.
- 65% of long-term survivors report good physical health, but only 55% good mental health.
- Insomnia affects 30-50% of cancer survivors for years after diagnosis.
- Among pediatric survivors, 25% have obesity rates higher than peers.
- 40% of survivors report limitations in daily activities due to health.
- Post-traumatic stress disorder (PTSD) occurs in 20% of long-term survivors.
- Only 23% of survivors meet aerobic activity guidelines, 14% strength training.
- 15-20% of survivors have peripheral neuropathy persisting >1 year post-chemo.
- Lymphedema affects 20% of breast cancer survivors long-term.
- 50% of head/neck cancer survivors report dysphagia impacting QoL.
- Fertility issues concern 70% of young adult survivors.
- 33% of survivors aged 65+ live alone, increasing isolation risk.
- Financial toxicity affects 42% of survivors with material hardship.
- Only 37% of survivors receive survivorship care plans.
- Cancer survivors have a 14% higher prevalence of arthritis.
- 28% of survivors report fair/poor general health vs. 17% controls.
- Among survivors, 12% have had ≥14 poor mental health days in past month.
Quality of Life Interpretation
The statistics reveal that surviving cancer is not a singular victory but an ongoing campaign against a daunting battalion of chronic physical, psychological, and social challenges that linger long after treatment ends.
Socioeconomic
- 18% of survivors unemployed 1-5 years post-diagnosis vs. 10% controls.
- Annual medical costs for survivors average $11,000 higher than non-cancer.
- 42% of survivors report financial hardship due to cancer costs.
- Working-age survivors have 30% lower household income post-diagnosis.
- 25% of survivors delay/forgo medical care due to cost.
- Cancer-related debt affects 33% of non-elderly survivors.
- Employment rate drops 20% within first year post-diagnosis for ages 18-64.
- Rural survivors 1.5 times more likely to be uninsured.
- Black survivors have 2x higher bankruptcy risk post-cancer.
- 60% of survivors aged 50-64 retire early due to cancer.
- Lost productivity costs US $16.9 billion annually from survivors.
- 15% of survivors lose employer-based health insurance.
- Low-income survivors (<$30k) have 40% lower survival rates.
- 70% of survivors use savings to cover treatment costs.
- Hispanic survivors 50% more likely to experience food insecurity.
- Disability claims rise 2.5-fold in first year post-diagnosis.
- Only 50% of survivors return to pre-diagnosis work hours.
- Medicare spending on survivors is $21 billion higher annually.
- 28% of young adult survivors (18-39) face job discrimination.
- Housing instability affects 12% of low-SES survivors.
- 35% of survivors report income decline >20% lasting 2+ years.
- Uninsured survivors 1.7x more likely to present with late-stage disease.
- Family caregivers lose $33 billion in wages yearly supporting survivors.
- 22% of survivors borrow money or take loans for treatment.
- Socioeconomic disparities lead to 15% lower 5-year survival in deprived areas.
- 45% of survivors underuse preventive services due to cost barriers.
- Long-term survivors (10+ years) still face 10% higher poverty rates.
Socioeconomic Interpretation
These statistics reveal a harsh, often hidden tumor metastasizing long after treatment ends: a financial malignancy that disproportionately devours the savings, income, security, and even the survival odds of those who have already battled for their lives.
Survival Rates
- The 5-year relative survival rate for all cancers combined (2017-2021) is 68.6% in the US.
- Breast cancer 5-year relative survival rate is 91.1% (2017-2021 SEER data).
- Prostate cancer 5-year survival rate reaches 97.1% for localized disease (2017-2021).
- Colorectal cancer overall 5-year survival is 65.2%, but 90.8% for localized (2017-2021).
- Lung cancer 5-year survival is 26.7% overall, 63.1% for localized stage (2017-2021).
- Melanoma of the skin has a 5-year survival of 94.7%, 99.6% localized (2017-2021).
- Bladder cancer 5-year survival is 78.8%, 96.3% for in situ (2017-2021).
- Kidney and renal pelvis cancer 5-year survival is 76.4% (2017-2021).
- Uterine corpus cancer 5-year survival rate is 84.5% (2017-2021 SEER).
- Thyroid cancer boasts a 98.7% 5-year survival rate (2017-2021).
- Non-Hodgkin lymphoma 5-year survival is 74.3% (2017-2021 data).
- Leukemia overall 5-year survival is 65.7%, 85.0% for lymphocytic types (2017-2021).
- Pancreatic cancer 5-year survival is only 12.5% (2017-2021 SEER).
- Liver and intrahepatic bile duct cancer 5-year survival is 20.8% (2017-2021).
- Ovarian cancer 5-year survival rate is 49.1% (2017-2021 data).
- Testicular cancer has a 95.3% 5-year survival rate (2017-2021).
- Hodgkin lymphoma survivors enjoy 89.2% 5-year survival (2017-2021).
- Brain and other nervous system cancers have 33.8% 5-year survival (2017-2021).
- Esophageal cancer 5-year survival is 21.0% (2017-2021 SEER data).
- Cervical cancer 5-year survival is 66.6% (2017-2021).
- Oral cavity and pharynx cancer 5-year survival is 68.5% (2017-2021).
- For all cancers, 10-year relative survival rate is 59.3% (2013-2019 SEER).
- Childhood cancer 5-year survival has improved to 86.0% for diagnoses 2014-2020.
- Black Americans have a 5-year survival rate of 63.5% vs. 70.9% for whites (all cancers).
- Localized stage cancers have 90.4% 5-year survival across all sites (2017-2021).
- Distant metastatic cancers have only 30.3% 5-year survival overall (2017-2021).
- 20-year survival for cancer survivors diagnosed at age 45-64 is 58% (SEER data).
Survival Rates Interpretation
These statistics tell a story of remarkable medical victories shadowed by stark realities, where your odds hinge critically on which organ is betrayed, how soon it's caught, and, unjustly, the color of your skin.
Sources & References
- Reference 1CANCERCONTROLcancercontrol.cancer.govVisit source
- Reference 2EUROPEANCANCEReuropeancancer.orgVisit source
- Reference 3CANCERcancer.govVisit source
- Reference 4SEERseer.cancer.govVisit source
- Reference 5IARCiarc.who.intVisit source
- Reference 6CANCERcancer.caVisit source
- Reference 7AIHWaihw.gov.auVisit source
- Reference 8CANCERRESEARCHUKcancerresearchuk.orgVisit source
- Reference 9PROGRESSREPORTprogressreport.cancer.govVisit source
- Reference 10PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 11CDCcdc.govVisit source
- Reference 12BCRFbcrf.orgVisit source
- Reference 13AJMCajmc.comVisit source
- Reference 14NCBIncbi.nlm.nih.govVisit source
- Reference 15AHAJOURNALSahajournals.orgVisit source
- Reference 16NEJMnejm.orgVisit source